Solanezumab
| Supplier | Creative Peptides |
|---|---|
| Product # | 10-101-180 |
| CAS # | 955085-14-0 |
| Pricing | Inquire |
| LabelingTarget | Amyloid precursor protein (APP) |
| MolecularFormula | C6396H9922N1712O1996S42 |
| MolecularWeight | 144000.1g/mol |
| Storage | -20°C |
| Explanation | Solanezumab is a humanized monoclonal IgG1 antibody which is directed against the mid-domain of the Aβ peptide. By sequestering Aβ, shifting equilibria between different species of Aβ, and removing small soluble species of Aβ that are directly toxic to synaptic function, it may exert benefit. |
| Application | Solanezumab, or sola, binds the amyloid-β peptides that aggregate and form plaques in the brain that are an early pathological feature of Alzheimer's disease. |
| AreasOfInterest | Neurological Disease |
| Disease | Alzheimer's disease |